US Patent 8,563,027: Claim Scope, Exclusivity, Orange Book Status, and Punctal-Plug Patent Landscape

US Patent 8,563,027 covers drug-delivering punctal plugs made from stretched, dehydrated, covalently crosslinked synthetic hydrogels. The independent claims require a specific combination of structure, manufacturing method, hydration behavior, ocular placement, and drug-release performance. The patent is most relevant to intracanalicular inserts that swell in the canaliculus and release ophthalmic drugs for at least six days.

The patent does not broadly cover every punctal plug, hydrogel insert, or sustained-release ophthalmic formulation. Infringement generally requires practice of each limitation in either process claim 1 or treatment-method claim 15, including the synthetic, polysaccharide-free, covalently crosslinked hydrogel and the stated expansion or release characteristics. The patent’s commercial relevance is greatest for drug-eluting intracanalicular inserts rather than conventional tear-drainage plugs.

What does US Patent 8,563,027 cover?

US Patent 8,563,027 covers two principal subject-matter groups:

A process for manufacturing a drug-loaded punctal plug.
A method of treating an eye condition by placing the drug-loaded hydrogel in a canaliculus.

The claims require a hydrogel that:

Is synthetic and water soluble before crosslinking.
Is free of polysaccharides.
Is covalently crosslinked.
Contains drug dispersed within the hydrogel.
Is stretched in length and dehydrated before placement.
Absorbs physiological water and expands in the canaliculus.
Directly contacts canalicular tissue after expansion.
Has a proximal face exposed to the tear film.
Has at least 50% water content when fully hydrated in physiological saline.

The claims also cover optional visualization or imaging agents, microparticles, corticosteroids, prostaglandin analogues, antibiotics, glaucoma drugs, anti-inflammatory drugs, and drugs used for retinal or macular conditions.

The patent claims are functional and structural. A competing device could avoid infringement by omitting one required limitation, such as the stretched and dehydrated configuration, the covalent crosslinking chemistry, the six-day tear-film release period, or the required water content.

What are the independent claims in US 8,563,027?

Claim 1: Manufacturing process for a drug-delivering punctal plug

Claim 1 requires a process that includes all of the following:

Limitation	Required scope
Device	Punctal plug for blocking or reducing tear flow
Drug delivery	Drug delivered to the eye
Matrix	Covalently crosslinked hydrogel
Polymer type	Synthetic water-soluble precursors
Composition	Hydrogel free of polysaccharides
Crosslinking	First and second functional groups react to form covalent bonds
Drug loading	Drug present during hydrogel formation and dispersed within the hydrogel
Configuration	Hydrogel stretched in length
Initial state	Dehydrated form
In-use state	Absorbs physiological water and swells
Tissue contact	Expanded hydrogel directly contacts canalicular tissue
Tear interface	Proximal face is in fluid communication with the tear film
Hydration	At least about 50% water by weight or volume after full in-vitro hydration

The claim is narrower than a generic process for loading a drug into a hydrogel. It requires drug presence during formation of the crosslinked network. A product in which drug is loaded after crosslinking may fall outside claim 1, although dependent claim 14 and other claim-construction issues would require separate analysis.

Claim 1 also requires a punctal-plug function. A hydrogel implant placed elsewhere in the eye or a drug-loaded ocular insert that does not block or reduce tear flow would not satisfy that limitation.

Claim 15: Treatment method

Claim 15 covers placing the specified hydrogel into a canaliculus to block or reduce tear flow and treat an eye condition. It requires:

A covalently crosslinked synthetic hydrogel.
A stretched and dehydrated configuration before placement.
Drug dispersed within the hydrogel.
Hydration and swelling in the canaliculus.
Direct tissue contact after expansion.
A proximal face exposed to tear fluid.
Drug release effective for at least about six days, measured by drug concentration in the tear film.

The six-day limitation is central. A plug that releases drug for only several hours or one to five days may not meet claim 15. A product with a longer release period could satisfy the limitation if the other elements are present.

Claim 15 is a method claim directed to treatment. It can create infringement exposure for use of a device, even if the device itself is supplied by another party. Claim 1 creates separate exposure for the manufacturing process.

How do the dependent claims expand the patent’s scope?

The dependent claims define several commercially important variations.

Hydrogel chemistry

Claims 7 through 9 address multi-functional covalent crosslinking systems. Claim 9 specifically covers a polyethylene glycol-based system in which succinimide groups react with amine or thiol groups.

This language is important because it reaches common in-situ-forming PEG hydrogel chemistry. A competitor using a PEG network with NHS-succinimide and amine or thiol reactions faces greater literal-scope risk than a competitor using a non-PEG hydrogel or a noncovalent gel.

Claim 18 covers a different pathway involving polymerizable groups initiated through free-radical polymerization. Claims 18 and 19 therefore extend beyond a single PEG-succinimide chemistry and reach certain alternative synthetic hydrogel networks.

Degradable hydrogels

Claims 6 and 17 cover hydrogels that spontaneously degrade through chemical hydrolysis in water. These limitations are narrower than the independent claims but commercially relevant to resorbable or bioerodible punctal plugs.

A hydrogel that remains structurally stable and is removed mechanically may not meet these dependent claims, although it could still fall within claims 1 or 15 if all independent-claim elements are present.

Drug categories

The claims name drugs including:

Latanoprost
Travoprost
Moxifloxacin
Brinzolamide
Betaxolol
Ciprofloxacin
Fluorometholone
Bimatoprost
Prednisolone
Cyclosporine
Loteprednol etabonate
Pegaptanib
Azelastine
Timolol

The claims also separately cover prostaglandin analogues and corticosteroids. The named-drug claims do not mean that the patent covers those drugs generally. The protection applies only when the named drug is used in the claimed punctal-plug process or treatment method.

Claim 20 contains apparent drafting issues, including the spelling "flluorometholone" and a repeated listing of travoprost. Those errors may be evaluated under claim-construction and prosecution-history principles. They do not automatically eliminate the broader prostaglandin-analogue or corticosteroid limitations.

Imaging and visualization

Claims 2 through 4 and 16 cover visualization agents that allow a patient or clinician to see the plug without machine assistance. Claims 25 through 28 cover imaging agents detectable with machine assistance, including fluorescent compounds.

The distinction is functional:

A visualization agent is visible to a human without a machine.
An imaging agent is detected using a machine or optical instrument.

Claim 3 covers agents contained in microspheres, microparticles, or microdroplets. Claim 4 covers agents covalently bound to the hydrogel.

Plug geometry

Claim 5 requires a proximal face and distal face joined by a side surface. The side surface must provide the tissue-contacting hydrogel and have an area at least twice the area of the proximal face.

This limitation favors elongated or substantially cylindrical expanded plugs. It is less likely to reach a flat, disc-shaped insert with a large proximal face and limited sidewall area.

Drug encapsulation

Claims 13 and 23 require the drug to be free of encapsulating materials. Claims 14 and 24 cover embodiments in which at least some drug is within microparticles.

These claims create overlapping but distinct positions:

Drug directly dispersed in the hydrogel and not encapsulated.
Drug incorporated into microparticles within the hydrogel.
Drug present in a composite system containing both free and microparticle-associated drug.

A competitor using liposomes, polymeric microspheres, nanoparticles, or another discrete carrier may avoid the "free of encapsulating materials" claims but could implicate the microparticle claims, depending on the construction of "microparticles."

What products are most exposed to US 8,563,027?

The highest-risk products have the following profile:

Product characteristic	Risk significance
Intracanalicular or punctal placement	High
Tear-flow reduction or punctal occlusion	High
Synthetic PEG hydrogel	High
Covalent crosslinking	High
Dehydrated insert that swells in situ	High
Drug present during crosslinking	High for claim 1
Drug dispersed directly in the hydrogel	High
At least six days of tear-film drug release	High for claim 15
Corticosteroid or prostaglandin analogue	Increases dependent-claim relevance
Hydrolysis-driven degradation	Increases claims 6 and 17 relevance
Fluorescent or visible marker	Increases claims 2-4 and 25-28 relevance

Lower-risk designs may include:

Noncovalently crosslinked hydrogels.
Polysaccharide-based matrices.
Preformed solid polymer inserts that do not hydrate and expand.
Devices that do not block or reduce tear flow.
Devices that release drug for less than six days.
Drug-loaded systems made by post-loading rather than incorporating drug during network formation.
Inserts placed on the ocular surface rather than in the canaliculus.

These design distinctions do not establish noninfringement by themselves. Claim scope depends on the full product and manufacturing record.

What is the Orange Book status of US 8,563,027?

US 8,563,027 is directed to a drug-delivery device, manufacturing process, and treatment method. It is not, based on the claim subject matter provided, a conventional active-ingredient patent for a drug substance.

Orange Book listing depends on whether the patent is submitted by an NDA holder as a patent that claims the approved drug, a method of using the drug, or the approved drug product. The FDA Orange Book does not automatically list every patent owned by a drug-device developer or every patent covering a potential use of an ophthalmic insert [2].

For an approved intracanalicular product, the relevant listing analysis would focus on:

Whether the NDA holder submitted the patent to FDA.
Whether the approved product uses the claimed hydrogel.
Whether the approved indication falls within claim 15 or its dependent claims.
Whether the patent was timely submitted under FDA listing regulations.
Whether the listed patent claims the approved product or an approved method of use.

The patent should not be treated as an Orange Book barrier solely because it covers a drug-eluting punctal plug. FDA listing must be confirmed in the current Orange Book patent listing and the applicable NDA patent-submission record.

When does US 8,563,027 lose exclusivity?

A United States utility patent generally expires 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments under 35 U.S.C. §§ 154 and 156 [3].

The issue date of US 8,563,027 was October 22, 2013. Its enforceable term is not determined by the issue date. The relevant analysis requires the patent’s priority chain, patent-term adjustment, and any terminal disclaimer recorded in USPTO records [1].

Because the claims cover an implant and method of treatment rather than the active drug alone, Hatch-Waxman five-year patent-term extension analysis would generally depend on whether the patent claims the approved product and whether the statutory requirements are satisfied. A patent-term extension cannot be assumed from FDA approval of a product using a similar hydrogel.

Are Paragraph IV challenges relevant?

A Paragraph IV certification is relevant when a generic applicant files an abbreviated new drug application and asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed [4].

The practical relevance of US 8,563,027 depends on whether it is listed against a specific approved ophthalmic product. If listed, a generic applicant could challenge it through:

A Paragraph IV certification.
A declaratory judgment action after the statutory notice process.
An ANDA litigation proceeding under 21 U.S.C. § 355(j).
A noninfringement position based on a different device structure or manufacturing process.

If the patent is not listed in the Orange Book, a Paragraph IV certification would not ordinarily be the principal pathway for challenging it. The patent holder could still pursue conventional patent litigation against an accused product.

Which companies and technologies compete with this patent estate?

The relevant competitive field includes four groups.

Drug-eluting punctal-plug developers

Ocular Therapeutix has been the principal commercial developer associated with intracanalicular hydrogel drug delivery, including Dextenza, an intracanalicular insert containing dexamethasone. FDA approved Dextenza for ocular itching associated with allergic conjunctivitis and later for inflammation and pain after ophthalmic surgery, subject to the approved labeling [5].

Other developers have pursued punctal plugs, intracanalicular inserts, hydrogel occlusion, and sustained ophthalmic delivery. The competitive risk does not come only from identical PEG chemistry. It also comes from alternative platforms that avoid one or more claim limitations.

Conventional punctal-plug manufacturers

Companies selling silicone, collagen, thermoplastic, acrylic, or other occlusive plugs may not practice the asserted claims because their products may lack:

A covalently crosslinked hydrogel.
Drug dispersion within the hydrogel.
A dehydrated, stretchable insert.
In-situ swelling.
Six-day drug release.

These products remain relevant prior art and potential design-around benchmarks.

Ocular drug-delivery platform companies

Competing delivery technologies include:

Ocular inserts placed in the conjunctival sac.
Contact-lens drug delivery.
Topical emulsions and suspensions.
Intravitreal implants.
Subconjunctival depots.
Biodegradable microparticle systems.

Those technologies may compete commercially with a drug-eluting punctal plug while falling outside the literal claims.

Active pharmaceutical ingredient owners

The patent’s named drugs include products associated with multiple originators and generic manufacturers. Those parties may have separate patents and regulatory exclusivities covering the active ingredient, formulation, indication, or delivery system. US 8,563,027 does not replace those rights and does not itself create exclusivity over latanoprost, moxifloxacin, corticosteroids, or other listed drugs.

How strong is the patent estate?

Strengths

The patent has meaningful scope where a product uses the full claimed architecture:

Synthetic, polysaccharide-free hydrogel.
Covalent network formation.
Dehydrated and stretched insert.
Expansion in the canaliculus.
Tissue contact after swelling.
Tear-film drug exposure.
Release for at least six days.

The combination of structural and functional limitations can make a direct design-around difficult if the commercial product is built around a swelling intracanalicular hydrogel.

Limitations

The claims also create several potential attack points:

"At least about 50%" water content may require factual testing and claim construction.
"Stretched in length" may be disputed for irregular or molded devices.
"Drug dispersed within the hydrogel" may not cover all post-loading approaches.
The six-day release period requires tear-film pharmacokinetic evidence.
Claims 1 and 15 are limited to punctal or canalicular use.
The patent does not broadly claim every drug-eluting ocular insert.
The patent’s effective term may be materially shorter than a later-filed continuation or improvement patent.

Validity challenges would likely focus on anticipation or obviousness based on earlier punctal plugs, synthetic hydrogels, in-situ swelling implants, drug-loaded hydrogels, and sustained ophthalmic delivery systems. The combination of all limitations, especially stretching, dehydration, expansion, tear-film exposure, and six-day release, is likely to be central to both validity and infringement disputes.

What manufacturing and IP barriers matter most?

Manufacturing records can determine whether a product falls within claim 1. Key evidence includes:

Identity and functionality of the precursor polymers.
Presence or absence of polysaccharides.
Whether crosslinking is covalent.
Whether the drug is present during network formation.
Whether the plug is stretched before dehydration.
Hydrated water content.
Microparticle or encapsulation status.
Degradation mechanism.
Release testing in tear fluid or simulated physiological media.

A company may avoid a process claim while still facing claim 15 if its finished product satisfies the treatment-method limitations. Conversely, a manufacturer may infringe claim 1 through production of a device even if the product is marketed for an indication outside the dependent method claims.

What patent litigation and settlement risks exist?

The most likely disputes involve:

Whether a competing insert is a "punctal plug" that blocks or reduces tear flow.
Whether a polymer network is covalently crosslinked.
Whether the hydrogel is synthetic and polysaccharide-free.
Whether the drug is dispersed within the hydrogel or separately encapsulated.
Whether the device is stretched and dehydrated.
Whether swelling produces direct canalicular tissue contact.
Whether drug release remains effective for at least six days.
Whether the accused product practices a claimed manufacturing step.

Settlement agreements in this field may include licenses, launch dates, geographic restrictions, authorized-generic arrangements, or covenants not to sue. A settlement cannot be inferred from patent ownership or FDA approval alone. Any freedom-to-operate conclusion must account for continuation patents, foreign counterparts, terminal disclaimers, and later patents covering specific commercial products.

Key Takeaways

US 8,563,027 targets drug-delivering punctal plugs made from stretched, dehydrated, covalently crosslinked synthetic hydrogels.
Claims 1 and 15 are the core claims: one covers manufacturing, and the other covers treatment.
The independent claims require more than a drug-loaded hydrogel. They require canalicular placement, swelling, tissue contact, tear-film communication, and specified hydration or release characteristics.
PEG-based systems using succinimide, amine, or thiol crosslinking face particular dependent-claim exposure.
Corticosteroids and prostaglandin analogues are expressly covered by dependent claims.
Claims cover both visible markers and machine-detectable imaging agents.
The patent should not be assumed to be Orange Book-listed without confirmation in the current FDA listing record.
Generic or competing-product risk depends heavily on the accused product’s manufacturing process and tear-film release data.
Conventional silicone or collagen punctal plugs generally present lower risk because they lack the claimed synthetic swelling hydrogel architecture.
The relevant patent estate must be reviewed with continuation patents, foreign counterparts, FDA listing records, and any patent-term adjustments.

FAQs About US Patent 8,563,027

Does US 8,563,027 cover Dextenza?

The claims are directed to a drug-delivering intracanalicular hydrogel insert architecture that is technically relevant to products such as Dextenza. Whether Dextenza practices a particular claim requires comparison of the approved product, formulation, manufacturing process, and release data with each claim limitation.

Does the patent cover a punctal plug made from silicone?

Probably not under the claims provided. Silicone does not ordinarily satisfy the claimed covalently crosslinked, synthetic, water-absorbing hydrogel that expands after placement and contains dispersed drug.

Is a six-day release period required for every claim?

No. The six-day release limitation appears in claim 15 and its dependent claims. Claim 1 instead requires the specified manufacturing process and hydrogel characteristics but does not expressly state the six-day release period.

Can a competitor avoid the patent by using a drug-loaded microparticle?

Not necessarily. Claims 14 and 24 expressly cover embodiments in which at least some drug is within microparticles. A microparticle design may avoid claims requiring drug free of encapsulating materials while remaining within the microparticle claims.

Does the patent cover treatment of glaucoma?

Yes, claim 22 expressly identifies elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The product must still satisfy the underlying hydrogel, canalicular-placement, and drug-release limitations of claim 15.

References

United States Patent and Trademark Office. (2013). U.S. Patent No. 8,563,027: Claims and patent record.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
35 U.S.C. §§ 154, 156.
21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2020). Dextenza prescribing information.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010213612	⤷ Start Trial
Australia	2010246115	⤷ Start Trial
Australia	2016201869	⤷ Start Trial
Australia	2018200074	⤷ Start Trial
Canada	2750242	⤷ Start Trial
Canada	2760704	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,563,027

Which drugs does patent 8,563,027 protect, and when does it expire?

Summary for Patent: 8,563,027